Want to see AU:PGC full AI Analyst Report?
PGC Stock Chart & Stats
AU$0.17
-AU$0.01(-2.04%)
At close: 4:00 PM EST
AU$0.17
-AU$0.01(-2.04%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.33
Previous CloseN/A
Volume365.08K
Average Volume (3M)417.19K
Market Cap
AU$223.47M
Enterprise ValueAU$588.69
Total Cash (Recent Filing)AU$23.68M
Total Debt (Recent Filing)AU$388.90M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.79%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,655,305,400
10 Day Avg. Volume500,163
30 Day Avg. Volume417,192
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)0.06
P/FCF Ratio-150.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.23Price Target Upside35.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$3.79B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained top-line growth indicates expanding demand for the company’s medical, scientific and clinical distribution offering. If retained, this scale can support broader customer coverage and improve the platform for future margin recovery.
Operating Cash Flow ReboundThe return to positive operating cash flow shows that the underlying business generated cash from operations in 2026. Although free cash flow remained negative, this rebound provides a foundation for improving liquidity and funding ongoing operations.
Integrated Healthcare Distribution ModelCombining product distribution with installation, maintenance and technical support broadens customer engagement beyond one-off equipment sales. Consumables and service activities can create follow-on revenue and strengthen the company’s role in clinical workflows.
Bears Say
Severe Margin CompressionThe sharp decline in gross margin and near break-even EBIT indicate that revenue growth is not currently translating into operating profitability. Persistent pricing, product-mix or cost pressure could limit earnings recovery and weaken the economics of scale.
Return To Net LossA return to losses reduces internally generated capital and makes performance more dependent on successful operational improvement. Continued negative earnings would constrain reinvestment capacity and increase sensitivity to execution or demand setbacks.
Higher Leverage And Weak Free Cash FlowRising leverage alongside negative free cash flow reduces financial flexibility and may limit the company’s ability to absorb further margin pressure. If cash conversion remains uneven, debt servicing and funding requirements could constrain strategic investment.
Paragon Care Limited News
PGC FAQ
What was Paragon Care Limited’s price range in the past 12 months?
Paragon Care Limited lowest share price was AU$0.13 and its highest was AU$0.33 in the past 12 months.
What is Paragon Care Limited’s market cap?
Paragon Care Limited’s market cap is AU$223.47M.
When is Paragon Care Limited’s upcoming earnings report date?
Paragon Care Limited’s upcoming earnings report date is Mar 04, 2027 which is in 157 days.
How were Paragon Care Limited’s earnings last quarter?
Paragon Care Limited released its earnings results on Aug 25, 2026. The company reported AU$0.008 earnings per share for the quarter.
Is Paragon Care Limited overvalued?
According to Wall Street analysts Paragon Care Limited’s price is currently Undervalued.
Does Paragon Care Limited pay dividends?
Paragon Care Limited pays a Semiannually dividend of AU$0.006 which represents an annual dividend yield of 2.79%. See more information on Paragon Care Limited dividends here
What is Paragon Care Limited’s EPS estimate?
Paragon Care Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paragon Care Limited have?
Paragon Care Limited has 1,655,305,400 shares outstanding.
What happened to Paragon Care Limited’s price movement after its last earnings report?
Paragon Care Limited reported an EPS of AU$0.008 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Paragon Care Limited?
Currently, no hedge funds are holding shares in AU:PGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Paragon Care Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.23 (35.29% Upside)
AU$0.23 (35.29% Upside)
Blogger Sentiment
Bullish
AU:PGC Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$27.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, breast milk tracking, electrodes; sterilisable transducers designed for surgical procedures, digital theatre integration, infection control, infusion therapy, temperature management, enteral feeding, pain management, lasers, operating room products, surgical consumables, and ultrasound systems. In addition, the company offers aesthetic devices for dermatologists, cosmetic surgeons, general practitioners, beauty and aesthetic providers, and educational institutions; natural, traditional, and complementary health products and services; critical care and dental solutions; urology solutions, such as shockwave therapy, lasers, and accessories for infection control; medical products and consumables; and orthopaedics solutions, including hip and knee arthroplasty, upper and lower extremity, sports medicine, reverse shoulder replacement, and powered surgical tools. Further, it offers medical equipment repair, maintenance, and support services; technology and communication solutions, such as telephony, nurse call, access control, cctv, cordless, and Wi-Fi; supplies medical equipment to veterans, war widows, and families; and veterinary products. Additionally, it is involved in maintenance of technical medical equipment to the health, aged care, and veterinary markets; and distribution of pharmaceuticals, medical consumables, and complementary medicines to Australian healthcare market. The company is based in Mount Waverley, Australia.
PGC Stock 12 Month Forecast
Average Price Target
AU$0.23
▲(35.29% Upside)
Technical Analysis
Sigma Healthcare Ltd
―
Polynovo
―
Compumedics Limited
―
Epsilon Healthcare Limited
―
Trajan Group Holdings Ltd
―